{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:13:05Z","timestamp":1774627985010,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81603055"],"award-info":[{"award-number":["No. 81603055"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13318-025-00983-y","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:48:57Z","timestamp":1768452537000},"page":"141-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal Physiologically-Based Pharmacokinetic Modeling to Predict Concentration\u2013Time Profiles of Poorly Soluble Cinacalcet Hydrochloride in Fasting and Fed State"],"prefix":"10.1007","volume":"51","author":[{"given":"Xiaoqian","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1263-5540","authenticated-orcid":false,"given":"Le","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"15","key":"983_CR1","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325. https:\/\/doi.org\/10.1056\/NEJMoa031633.","journal-title":"N Engl J Med"},{"issue":"2","key":"983_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004;308(2):627\u201335. https:\/\/doi.org\/10.1124\/jpet.103.057273.","journal-title":"J Pharmacol Exp Ther"},{"key":"983_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.podrm.2017.02.001","volume":"42","author":"GAE Mostafa","year":"2017","unstructured":"Mostafa GAE, Al-Badr AA. Cinacalcet hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2017;42:1\u201390. https:\/\/doi.org\/10.1016\/bs.podrm.2017.02.001.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"10","key":"983_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4631","volume":"33","author":"LL Li","year":"2019","unstructured":"Li LL, Chen CL, Cai NF, et al. An improved LC-MS\/MS method for determination of cinacalcet in human plasma and its application to the evaluation of food intake effect on the pharmacokinetics of cinacalcet in healthy volunteers. Biomed Chromatogr. 2019;33(10):e4631. https:\/\/doi.org\/10.1002\/bmc.4631.","journal-title":"Biomed Chromatogr"},{"issue":"3","key":"983_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.mjt.0000212703.71625.26","volume":"14","author":"D Padhi","year":"2007","unstructured":"Padhi D, Salfi M, Harris RZ. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. Am J Ther. 2007;14(3):235\u201340. https:\/\/doi.org\/10.1097\/01.mjt.0000212703.71625.26.","journal-title":"Am J Ther"},{"issue":"2","key":"983_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.33594\/000000148","volume":"53","author":"G Schappacher-Tilp","year":"2019","unstructured":"Schappacher-Tilp G, Fuertinger DH, Kotanko P. A multi-compartment model capturing the pharmacokinetics of the calcimimetic cinacalcet. Cell Physiol Biochem. 2019;53(2):429\u201338. https:\/\/doi.org\/10.33594\/000000148.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"983_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303\u201311. https:\/\/doi.org\/10.2165\/00003088-200948050-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"983_CR8","first-page":"1667","volume":"53","author":"L Liu","year":"2018","unstructured":"Liu L, Ren LL. Preparation of Cinacalcet nanoemulsion and its in vivo and in vitro evaluation. Chin Pharm. 2018;53(19):1667\u201375.","journal-title":"Chin Pharm"},{"issue":"12","key":"983_CR9","first-page":"1673","volume":"29","author":"XW Wu","year":"2018","unstructured":"Wu XW, Sun ZX. Study on the in vivo-in vitro correlation of Cinacalcet hydrochloride tablets. Chin Pharm. 2018;29(12):1673\u20137.","journal-title":"Chin Pharm"},{"issue":"21","key":"983_CR10","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-1329","volume":"8","author":"YJ Liu","year":"2020","unstructured":"Liu YJ, Sun LN, Cheng ZP, et al. Pharmacogenetic and safety analysis of cinacalcet hydrochloride in healthy Chinese subjects. Ann Transl Med. 2020;8(21):1385. https:\/\/doi.org\/10.21037\/atm-20-1329.","journal-title":"Ann Transl Med"},{"key":"983_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-1-4684-6036-0_25","volume":"423","author":"H Malinowski","year":"1997","unstructured":"Malinowski H, Marroum P, Uppoor VR, et al. Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol. 1997;423:269\u201388. https:\/\/doi.org\/10.1007\/978-1-4684-6036-0_25.","journal-title":"Adv Exp Med Biol"},{"key":"983_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2017.02.029","volume":"102","author":"MA Nguyen","year":"2017","unstructured":"Nguyen MA, Flanagan T, Brewster M, et al. A survey on IVIVC\/IVIVR development in the pharmaceutical industry\u2014past experience and current perspectives. Eur J Pharm Sci. 2017;102:1\u201313. https:\/\/doi.org\/10.1016\/j.ejps.2017.02.029.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"983_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1208\/s12248-019-0292-3","volume":"21","author":"C Stillhart","year":"2019","unstructured":"Stillhart C, Pepin X, Tistaert C, et al. PBPK absorption modeling: establishing the In Vitro-In Vivo link-industry perspective. AAPS J. 2019;21(2):19. https:\/\/doi.org\/10.1208\/s12248-019-0292-3.","journal-title":"AAPS J"},{"key":"983_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010074","author":"M Bermejo","year":"2020","unstructured":"Bermejo M, Hens B, Dickens J, et al. A mechanistic physiologically-based biopharmaceutics modeling (PBBM) approach to assess the in vivo performance of an orally administered drug product: from IVIVC to IVIVP. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12010074.","journal-title":"Pharmaceutics"},{"key":"983_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejpb.2022.05.007","volume":"176","author":"S Subhani","year":"2022","unstructured":"Subhani S, Kim C, Muniz P, et al. Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products. Eur J Pharm Biopharm. 2022;176:87\u201394. https:\/\/doi.org\/10.1016\/j.ejpb.2022.05.007.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"983_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0378-5173(99)00147-7","volume":"186","author":"LX Yu","year":"1999","unstructured":"Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186(2):119\u201325. https:\/\/doi.org\/10.1016\/s0378-5173(99)00147-7.","journal-title":"Int J Pharm"},{"issue":"9","key":"983_CR17","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1023\/a:1018917729477","volume":"10","author":"AT Lu","year":"1993","unstructured":"Lu AT, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 1993;10(9):1308\u201314. https:\/\/doi.org\/10.1023\/a:1018917729477.","journal-title":"Pharm Res"},{"issue":"1","key":"983_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67\u201386. https:\/\/doi.org\/10.1007\/s10928-011-9232-2.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"983_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1124\/dmd.104.000604","volume":"32","author":"GN Kumar","year":"2004","unstructured":"Kumar GN, Sproul C, Poppe L, et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos. 2004;32(12):1491\u2013500. https:\/\/doi.org\/10.1124\/dmd.104.000604.","journal-title":"Drug Metab Dispos"},{"key":"983_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121415","volume":"614","author":"I Camara-Martinez","year":"2022","unstructured":"Camara-Martinez I, Blechar JA, Ruiz-Picazo A, et al. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen. Int J Pharm. 2022;614:121415. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121415.","journal-title":"Int J Pharm"},{"key":"983_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0378-5173(98)00174-4","volume":"171","author":"LX Yu","year":"1998","unstructured":"Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans. Int J Pharm. 1998;171:157\u201363.","journal-title":"Int J Pharm"},{"key":"983_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0378-5173(96)04592-9","volume":"140","author":"LX Yu","year":"1996","unstructured":"Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm. 1996;140:111\u20138.","journal-title":"Int J Pharm"},{"issue":"1","key":"983_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.xphs.2018.07.023","volume":"108","author":"CR Honigford","year":"2019","unstructured":"Honigford CR, Aburub A, Fadda HM. A simulated stomach duodenum model predicting the effect of fluid volume and prandial gastric flow patterns on nifedipine pharmacokinetics from cosolvent-based capsules. J Pharm Sci. 2019;108(1):288\u201394. https:\/\/doi.org\/10.1016\/j.xphs.2018.07.023.","journal-title":"J Pharm Sci"},{"issue":"6","key":"983_CR24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s11095-006-0162-4","volume":"23","author":"R Takano","year":"2006","unstructured":"Takano R, Sugano K, Higashida A, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006;23(6):1144\u201356. https:\/\/doi.org\/10.1007\/s11095-006-0162-4.","journal-title":"Pharm Res"},{"issue":"5","key":"983_CR25","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.clinthera.2012.03.058","volume":"34","author":"S Lee","year":"2012","unstructured":"Lee S, Gu N, Kim BH, et al. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. Clin Ther. 2012;34(5):1160\u20139. https:\/\/doi.org\/10.1016\/j.clinthera.2012.03.058.","journal-title":"Clin Ther"},{"issue":"3","key":"983_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0939-6411(03)00140-1","volume":"56","author":"F Langenbucher","year":"2003","unstructured":"Langenbucher F. Handling of computational in vitro\/in vivo correlation problems by Microsoft Excel: III. Convolution and deconvolution. Eur J Pharm Biopharm. 2003;56(3):429\u201337. https:\/\/doi.org\/10.1016\/s0939-6411(03)00140-1.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"983_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1023\/a:1015195612726","volume":"19","author":"Y Wang","year":"2002","unstructured":"Wang Y, Nedelman J. Bias in the Wagner\u2013Nelson estimate of the fraction of drug absorbed. Pharm Res. 2002;19(4):470\u20136. https:\/\/doi.org\/10.1023\/a:1015195612726.","journal-title":"Pharm Res"},{"key":"983_CR28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.16522\/j.cnki.cjph.2016.08.020","volume":"47","author":"WZ Liu","year":"2016","unstructured":"Liu WZ, Li LL, Li ZY. In vitro dissolution consistency evaluation of cinacalcet hydrochloride tablets. Chin J Pharm. 2016;47:1047\u201351. https:\/\/doi.org\/10.16522\/j.cnki.cjph.2016.08.020.","journal-title":"Chin J Pharm"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00983-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00983-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00983-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:23:50Z","timestamp":1774625030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00983-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00983-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Ethical review and approval were not provided for this study on human participants because the human data used in this study were all cited from references. We did not conduct any human subject research by ourselves.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This study does not involve human participants, animals, or any other research subjects. Therefore, consent to participate is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"No personally identifiable information of participants is included in this manuscript, so consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors confirm that the data and material supporting the findings of this study is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The authors confirm that the code supporting the findings of this study is available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Xiaoqian Xie: methodology, validation, writing\u2014original draft; Le Sun: investigation, methodology, writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"The authors confirm that the data that support the findings of this study are available from the corresponding author upon reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}}]}}